Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$151.26 USD
-2.17 (-1.41%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $151.34 +0.08 (0.05%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Ascendis Pharma AS falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 432 | 775 | 807 | 821 | 670 |
Receivables | 60 | 27 | 27 | 8 | 6 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 226 | 138 | 89 | 0 | 0 |
Other Current Assets | 42 | 33 | 30 | 16 | 9 |
Total Current Assets | 761 | 973 | 953 | 845 | 685 |
Net Property & Equipment | 120 | 136 | 149 | 124 | 50 |
Investments & Advances | 6 | 32 | 173 | 142 | 17 |
Other Non-Current Assets | 2 | 2 | 2 | 2 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 5 | 5 | 6 | 7 | 4 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 2 |
Total Assets | 894 | 1,148 | 1,284 | 1,119 | 758 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 102 | 106 | 70 | 25 | 31 |
Current Portion Long-Term Debt | 12 | 27 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 2 | 6 | 0 | 0 | 0 |
Other Current Liabilities | 81 | 41 | 48 | 27 | 16 |
Total Current Liabilities | 214 | 180 | 119 | 60 | 54 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 578 | 509 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 168 | 181 | 4 | 4 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,051 | 871 | 238 | 161 | 89 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 8 | 8 | 9 | 8 | 7 |
Capital Surplus | 2,298 | 2,226 | 2,494 | 1,975 | 1,257 |
Retained Earnings | -2,465 | -1,960 | -1,673 | -1,177 | -685 |
Other Equity | 1 | 4 | 241 | 152 | 89 |
Treasury Stock | 0 | 0 | 26 | 0 | 0 |
Total Shareholder's Equity | -158 | 277 | 1,045 | 958 | 669 |
Total Liabilities & Shareholder's Equity | 894 | 1,148 | 1,284 | 1,119 | 758 |
Total Common Equity | -158 | 277 | 1,045 | 958 | 669 |
Shares Outstanding | 57.70 | 57.00 | 56.80 | 53.40 | 42.10 |
Book Value Per Share | -2.73 | 4.87 | 18.41 | 17.94 | 15.89 |
Fiscal Year End for Ascendis Pharma AS falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 279 | 348 | 432 | 496 | 470 |
Receivables | 87 | 75 | 60 | 54 | 39 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 271 | 253 | 226 | 206 | 183 |
Other Current Assets | 40 | 46 | 42 | 42 | 47 |
Total Current Assets | 676 | 721 | 761 | 798 | 739 |
Net Property & Equipment | 112 | 116 | 120 | 137 | 137 |
Investments & Advances | 22 | 27 | 6 | 9 | 15 |
Other Non-Current Assets | 2 | 2 | 2 | 2 | 2 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 5 | 5 | 5 | 5 | 5 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 817 | 871 | 894 | 950 | 898 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 107 | 103 | 102 | 132 | 133 |
Current Portion Long-Term Debt | 660 | 691 | 12 | 13 | 29 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 1 | 4 | 2 | 7 | 6 |
Other Current Liabilities | 145 | 70 | 81 | 64 | 41 |
Total Current Liabilities | 913 | 867 | 214 | 232 | 210 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 8 | 8 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 236 | 249 | 578 | 598 | 523 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 168 | 103 | 95 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1,162 | 1,130 | 1,051 | 1,030 | 828 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 8 | 8 | 8 | 8 | 8 |
Capital Surplus | 2,310 | 2,328 | 2,298 | 2,309 | 2,306 |
Retained Earnings | -2,664 | -2,596 | -2,465 | -2,399 | -2,245 |
Other Equity | 1 | 1 | 1 | 2 | 2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -346 | -259 | -158 | -80 | 71 |
Total Liabilities & Shareholder's Equity | 817 | 871 | 894 | 950 | 898 |
Total Common Equity | -346 | -259 | -158 | -80 | 71 |
Shares Outstanding | 58.20 | 58.20 | 57.70 | 57.60 | 57.30 |
Book Value Per Share | -5.94 | -4.44 | -2.73 | -1.39 | 1.23 |